Achieving Optimal Treatment Targets and Minimal Disease Activity with Upadacitinib for Moderate-to-Severe Atopic Dermatitis: Integrated Analysis of Phase 3 Studies (Measure Up 1 and 2)Jonathan I. Silverberg, Andreas Wollenberg, Norito Katoh et al.|Dermatology and Therapy|2025Cited by 4